These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 19128974)

  • 21. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats.
    Hara T; Yokoyama A; Tanabe K; Ishihara H; Iwamoto M
    Thromb Haemost; 1995 Aug; 74(2):635-9. PubMed ID: 8584999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
    Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
    J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement of low bioavailability of a novel factor Xa inhibitor through formulation of cationic additives in its oral dosage form.
    Fujii Y; Kanamaru T; Kikuchi H; Nakagami H; Yamashita S; Akashi M; Sakuma S
    Int J Pharm; 2011 Dec; 421(2):244-51. PubMed ID: 22001539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Haginoya N; Kobayashi S; Nagata T; Mochizuki A; Suzuki M; Yoshino T; Horino H; Nagahara T; Suzuki M; Isobe Y; Furugoori T
    Bioorg Med Chem; 2005 Jun; 13(12):3927-54. PubMed ID: 15911309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SAR.
    Zhang P; Bao L; Fan J; Jia ZJ; Sinha U; Wong PW; Park G; Hutchaleelaha A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2186-9. PubMed ID: 19297158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.
    Lam PY; Clark CG; Li R; Pinto DJ; Orwat MJ; Galemmo RA; Fevig JM; Teleha CA; Alexander RS; Smallwood AM; Rossi KA; Wright MR; Bai SA; He K; Luettgen JM; Wong PC; Knabb RM; Wexler RR
    J Med Chem; 2003 Oct; 46(21):4405-18. PubMed ID: 14521405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
    Quan ML; Lam PY; Han Q; Pinto DJ; He MY; Li R; Ellis CD; Clark CG; Teleha CA; Sun JH; Alexander RS; Bai S; Luettgen JM; Knabb RM; Wong PC; Wexler RR
    J Med Chem; 2005 Mar; 48(6):1729-44. PubMed ID: 15771420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides.
    Chan C; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chaudry L; Chung CW; Convery MA; Hamblin JN; Johnstone L; Kelly HA; Kleanthous S; Patikis A; Patel C; Pateman AJ; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE; Whitworth C; Young RJ; Zhou P
    J Med Chem; 2007 Apr; 50(7):1546-57. PubMed ID: 17338508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.
    Nagahara T; Yokoyama Y; Inamura K; Katakura S; Komoriya S; Yamaguchi H; Hara T; Iwamoto M
    J Med Chem; 1994 Apr; 37(8):1200-7. PubMed ID: 8164262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
    Shi Y; O'Connor SP; Sitkoff D; Zhang J; Shi M; Bisaha SN; Wang Y; Li C; Ruan Z; Lawrence RM; Klei HE; Kish K; Liu EC; Seiler SM; Schweizer L; Steinbacher TE; Schumacher WA; Robl JA; Macor JE; Atwal KS; Stein PD
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7516-21. PubMed ID: 22041058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DX-9065a Daiichi.
    Kaiser B
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1105-12. PubMed ID: 14582456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue: part 2.
    Stürzebecher A; Dönnecke D; Schweinitz A; Schuster O; Steinmetzer P; Stürzebecher U; Kotthaus J; Clement B; Stürzebecher J; Steinmetzer T
    ChemMedChem; 2007 Jul; 2(7):1043-53. PubMed ID: 17541992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography.
    Nazaré M; Will DW; Matter H; Schreuder H; Ritter K; Urmann M; Essrich M; Bauer A; Wagner M; Czech J; Lorenz M; Laux V; Wehner V
    J Med Chem; 2005 Jul; 48(14):4511-25. PubMed ID: 15999990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and biological evaluation of the metabolites of 2-(1-{3-[(6-chloronaphthalen-2-yl)sulfonyl]propanoyl}piperidin-4-yl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one.
    Fujimoto T; Tobisu M; Konishi N; Kawamura M; Tada N; Takagi T; Kubo K
    Bioorg Med Chem; 2009 Dec; 17(23):7993-8002. PubMed ID: 19861238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Orally active zwitterionic factor Xa inhibitors with long duration of action.
    Mochizuki A; Nagata T; Kanno H; Takano D; Kishida M; Suzuki M; Ohta T
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7337-43. PubMed ID: 22044620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor.
    Hirayama F; Koshio H; Katayama N; Kurihara H; Taniuchi Y; Sato K; Hisamichi N; Sakai-Moritani Y; Kawasaki T; Matsumoto Y; Yanagisawa I
    Bioorg Med Chem; 2002 May; 10(5):1509-23. PubMed ID: 11886813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, and biological activity of piperidine diamine derivatives as factor Xa inhibitor.
    Mochizuki A; Nakamoto Y; Naito H; Uoto K; Ohta T
    Bioorg Med Chem Lett; 2008 Jan; 18(2):782-7. PubMed ID: 18039572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors.
    Ye B; Arnaiz DO; Chou YL; Griedel BD; Karanjawala R; Lee W; Morrissey MM; Sacchi KL; Sakata ST; Shaw KJ; Wu SC; Zhao Z; Adler M; Cheeseman S; Dole WP; Ewing J; Fitch R; Lentz D; Liang A; Light D; Morser J; Post J; Rumennik G; Subramanyam B; Sullivan ME; Vergona R; Walters J; Wang YX; White KA; Whitlow M; Kochanny MJ
    J Med Chem; 2007 Jun; 50(13):2967-80. PubMed ID: 17536795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part II: exploration of 6-6 fused rings as alternative S1 moieties.
    Yoshikawa K; Kobayashi S; Nakamoto Y; Haginoya N; Komoriya S; Yoshino T; Nagata T; Mochizuki A; Watanabe K; Suzuki M; Kanno H; Ohta T
    Bioorg Med Chem; 2009 Dec; 17(24):8221-33. PubMed ID: 19900814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
    Lee K; Park CW; Jung WH; Park HD; Lee SH; Chung KH; Park SK; Kwon OH; Kang M; Park DH; Lee SK; Kim EE; Yoon SK; Kim A
    J Med Chem; 2003 Aug; 46(17):3612-22. PubMed ID: 12904065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.